VC/PE/M&A. Healthcare Weekly(海外版)(2017.11.07)

 2017-11-08 A- A+

作者:克莱尔

> Frazier Healthcare Partners火热募资,4.19亿元志在投资早期生命科学。

> 多种场景,多种应对——西门子医疗收购Epocal,扩充血液即时诊断系统。

> 研发项目ROI不等同于长远意义,三家机构联手开展阿兹海默症防治研究。

私募融资 & IPO

1. Frazier Healthcare Partners火热募资,4.19亿美元志在早期生命科学

概要:位于美国加州的医疗投资机构Frazier Healthcare Partners的Frazier Life Sciences IX基金目前募资达到4.19亿美元(超募),计划2/3用于种子期和A轮的生命科学投资,并着重关注从潜伏期到临床期的药物研发。据称,其投资适应症主要包括血液肿瘤学、免疫肿瘤学、抗感染药、孤儿病治疗等。

相关报道:

Frazier Healthcare Partners hits $419M for early-stage biotechplay

Nov 1, 2017

California investment firm Frazier Healthcare Partners has gone over its hard cap target of $400 million as it looks toinject cash into early life science work. The company, which saw $419 million in total capital commitments, will look to build on its historic work that has typically focused on drugs making the transition from preclinical through clinical proof-of-concept. The so-called Frazier Life Sciences IX marks its second dedicated Life Sciences fund; back in 2015, it unveiled its firstpure play in this sector, with a $262 million raise.

Frazier Life Sciences IX will target two-thirds of its investments in early seed and series A rounds, with many ofthese investments expected to come from the team’s company creation efforts. Asked about which therapy areas, if any inparticular, would be its focus, the company said “We do not focus on any onetherapeutic area,” but historic areas of investment have included a range ofdisease areas, including hematologic oncology, immuno-oncology, anti-infectives,orphan diseases, diseases, pain, and many others.

Source: FierceBiotech

http://www.fiercebiotech.com/biotech/frazier-healthcare-partners-hits-419m-for-early-stage-biotech-play

并购

1. 多种场景,多种应对——西门子医疗收购Epocal,扩充血液即时诊断系统

概要:西门子医疗近日宣布,从美利艾尔(Alere)和雅培(Abbott)手中收购了血液即时诊断业务Epocal。交易的具体金额未透露。西门子医疗表示将把Epocal并入自己的即时诊断生态系统,从而为医师办公室、诊所、急救室甚至救护车等多种场景提供针对性的血液气压监测服务。Epocal主要生产手持无线血液分析系统Epoc,用于在30秒内解析血液气压、电解质、代谢物等的结果。

Epocal的血液即时监测产品

相关报道:

Siemens Healthineers closes Epocal buy

Nov 1, 2017

Siemens (NYSE:SI) Healthineers said today itclosed its acquisition of the Epocal point-of-care blood diagnostic businessfrom Alere and Abbott (NYSE:ABT) for an undisclosed amount. Siemens Healthineers said it will integrate Epocal’s portfolio into its POC Ecosystem solution to offer customized testing and touted that the two lines would “integrate seamlessly.” “Health networks have varying needs for blood gas testing across physicians’ offices, clinics, emergency departments, laboratories and even in ambulances. Having any one solution is limiting and may not meet all patient needs, which is why customized testing solutions are so important for improving patient care. With a complete offering for blood gas diagnostics, we can help healthcare providers and point-of-care coordinators improve their workflows by offering the right test in the right setting at the right time,”Siemens point-of-care diag biz prez Peter Koerte said in a press release. Epocal produces the handheld wireless Epocblood analysis system designed to analyze blood gas, electrolyte and metabolite results in approximately 30 seconds after blood sample introduction, Siemenssaid. The system is comprised of the Epoc room-temperature stable BEM testcard, Epoc reader and Epoc host2 mobile computer. A range of tests can be performed on the BGEM card, the company added. Siemens announced the deal to acquire Epocalfrom Alere in July as it looked to clear regulatory hurdles in its acquisitionby Abbott, which closed early last month.

Source: MassDevice

http://www.massdevice.com/siemens-healthineers-closes-epocal-buy/

行业盘点

1. 如何评价研发项目ROI与长远意义?三家机构联手开展阿兹海默症防治研究

概要:过去15年来,关于阿兹海默症治疗方案的研发一直有一个严酷的现实:研发过程中似乎有很多天花乱坠的宣传、让人信以为真的希望,但是当数据检测那一天,一切幻想都破灭了。在过去的研发表明,大脑中的淀粉样蛋白组成的粘斑是导致阿兹海默症的元凶,而BACE抑制剂似乎能够抑制其生成。尽管过去礼来、罗氏、默克、辉瑞等公司对BACE抑制剂的研究都没有得出明显的反应,许多公司仍然在孜孜不倦地进行这项研究。近日,诺华、安进、Banner Alzheimer’s Institute等机构将共同开展一项名为“Generation Study 2”的、使用BACE抑制剂CNP520的全球防治项目。这三家机构之前已经共同开展了“Generation Study 1”,但是称目前这一项目规模更大,针对的高危群体更广。目前,该项目进度已进入2/3。

相关报道:

Novartis, Amgen and Banner aim for Alzheimer’s prevention with new BACE trials

Nov 2, 2017

It’s a depressingly familiar story in Alzheimer’s R&D: a lot of hype, sprinkles of hope, but then dashed when data day comes around. We’ve seen it time and time again over the past 15 years from a particularly cruel disease that robs people of their memories and eventually kills them. One of the main features of research in the sector has been the use of BACE inhibitors that are believed to slow down the buildup of sticky plaques of amyloid in the brain, which many see as a primary culprit of the disease. But this research has so far failed to show a strong response in testing, with even the likes of Eli Lilly, Roche, Merck and Pfizer making no headway, although there is still some sentiment from analysts that Biogen’s aducanumab, which goes after the same target, can produce something other than failure.

Despite severely limited ROI in this area, some are still going after the disease, which affects around 44 million people around the world and thus remains a major unmet medical need, as well as a massive revenue potential if someone could get it right in testing. Today, Novartis, Amgen and Banner Alzheimer’s Institute will begin collaborating on a major global prevention program called "Generation Study 2," using the BACE inhibitor CNP520. The idea is that this drug can prevent or delay symptoms of Alzheimer’s disease (AD). The new trials will include people who are cognitively healthy but at genetic risk of developing AD by carrying either two copies of the apolipoprotein E (APOE) 4 gene (which is a risk factor for the disease), or one copy of the gene with evidence of elevated brain amyloid. Around one in four people carry a single copy of the APOE4 gene, but only about 2% of the world’s population carries two copies. The three are already working on Generation Study 1 using the BACE inhibitor, but say this second test is bigger and aims to go for a broader, at-risk population, as GS1 is only testing on those with two copies of the gene. The programs are in phase 2/3. GS2 started enrolling participants in the U.S. back in August but will eventually include more than 180 sites in more than 20 countries around the world (with 80 sites in the U.S.), and is aiming for 2,000 patients. These patients will be randomized to receive a dummy treatment or one of two doses (15 mg or the higher 50 mg) of CNP520, which has been co-developed by Novartis and Amgen. “Expanding our collaboration with Banner Alzheimer’s Institute stands testament to our belief that preventing amyloid buildup is one of the most promising approaches to treating Alzheimer’s disease,” said Vas Narasimhan, M.D., CMO for Novartis and soon to be its new CEO. “If we determine that our BACE1 inhibitor can prevent or delay the onset of symptoms in healthy yet high-risk populations, this would represent a tremendous breakthrough for those that may face this debilitating disease.” “This expanded collaboration builds upon the API Generation Study 1 which launched last year, and is another step in our effort to take clinical trials to a critical new stage,” added Pierre Tariot, M.D., co-director of API and director of BAI, a division of Banner Health, one of the largest nonprofit healthcare systems in the U.S. “This approach continues to shift the Alzheimer’s research paradigm from reversing disease damage to attacking its root cause before symptoms surface. It is our hope that by targeting people earlier, we will have a better chance of delaying or preventing the onset of the disease.” Thousands of people around the U.S. are making that decision in their living rooms and kitchens, and it’s a pretty amazing phenomenon. We really want people to understand, not only how revolutionary these studies are, but also how revolutionary the outreach and recruitment efforts have been for this.”

Source: FiercePharma

http://www.fiercebiotech.com/biotech/novartis-amgen-and-banner-aim-for-alzheimer-s-prevention-new-bace-trials

以上,难免有疏漏或不正确之处,请多多指出,并在文下留言处留言,谢谢!

*声明:本文由入驻新浪医药新闻作者撰写,观点仅代表作者本人,不代表新浪医药新闻立场。
收藏
扫描二维码,关注新浪医药(sinayiyao)公众号
360°纵览医药全局,365天放送新闻时事,医药资讯轻松一览,
精彩不容错过。
文章评论
肖恩大侠 华盖医疗基金董事总经理,北京。 毕业于北京大学工学院医学院(医学硕士)、北京大学法学院(法学硕士)。资浅PE从业人士。躬耕于太湖,游学至未名,当过医生,学过法律,改行至风险投资,喜好读书写作,经史文集,现代科技都甚喜欢,总是怀着理想,万一,实现了呢?欢迎交流医疗、文化、消费,欢迎交流一级市场、二级市场,欢迎交流国内及海外并购。 邮箱:shawn.shiqq.com
+订阅
印象笔记
有道云笔记
微信
二维码
意见反馈